Cytori Therapeutics (NASDAQ: CYTX) and SurModics (NASDAQ:SRDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Volatility & Risk

Cytori Therapeutics has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500. Comparatively, SurModics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cytori Therapeutics and SurModics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics 0 1 1 0 2.50
SurModics 0 0 2 0 3.00

Cytori Therapeutics currently has a consensus price target of $3.65, indicating a potential upside of 942.86%. SurModics has a consensus price target of $40.00, indicating a potential upside of 37.93%. Given Cytori Therapeutics’ higher probable upside, equities research analysts plainly believe Cytori Therapeutics is more favorable than SurModics.

Insider & Institutional Ownership

7.4% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of SurModics shares are owned by institutional investors. 1.9% of Cytori Therapeutics shares are owned by insiders. Comparatively, 7.7% of SurModics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cytori Therapeutics and SurModics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytori Therapeutics $4.66 million 2.64 -$22.04 million ($0.90) -0.39
SurModics $73.11 million 5.24 $3.92 million $0.29 100.00

SurModics has higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than SurModics, indicating that it is currently the more affordable of the two stocks.


This table compares Cytori Therapeutics and SurModics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytori Therapeutics -367.33% -228.21% -69.19%
SurModics 1.99% 1.45% 1.20%


SurModics beats Cytori Therapeutics on 12 of the 14 factors compared between the two stocks.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

SurModics Company Profile

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.